Cerevel Therapeutics Holdings Management
Management criteria checks 2/4
Cerevel Therapeutics Holdings' CEO is Ron Renaud, appointed in Jun 2023, has a tenure of less than a year. directly owns 0.13% of the company’s shares, worth $10.31M. The average tenure of the management team and the board of directors is 3.3 years and 5 years respectively.
Key information
Ron Renaud
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | 0.1% |
Management average tenure | 3.3yrs |
Board average tenure | 5yrs |
Recent management updates
Recent updates
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Dosing underway in Cerevel Therapeutics' tavapadon trials for Parkinson’s disease
Oct 30CEO
Ron Renaud (54 yo)
less than a year
Tenure
Mr. Ronald C. Renaud, also known as Ron, Jr., M.B.A., serves as President, CEO & Director at Cerevel Therapeutics Holdings, Inc. since June 12, 2023. He served as Managing Director at Bain Capital Life Sci...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 5.3yrs | US$11.23m | 0.0086% $ 659.6k | |
VP of Finance & Chief Accounting Officer | 4.5yrs | US$1.58m | 0.0098% $ 747.7k | |
Chief Scientific Officer | 4.9yrs | US$4.78m | 0.0035% $ 268.9k | |
Chief Medical Officer | 5.2yrs | US$4.81m | 0.0081% $ 619.0k | |
President | less than a year | no data | 0.13% $ 10.3m | |
Chief Financial Officer | less than a year | no data | 0.0093% $ 713.2k | |
Vice President of Investor Relations | no data | no data | no data | |
Chief Legal Officer & Corporate Secretary | 2.8yrs | US$3.19m | 0.0040% $ 305.7k | |
Chief Human Resources Officer | 4.9yrs | no data | 0.014% $ 1.0m | |
Chief Corporate Affairs Officer | 3.7yrs | US$3.92m | 0.0059% $ 449.7k | |
Chief Business Development & Strategic Operations Officer | less than a year | no data | 0.025% $ 1.9m |
3.3yrs
Average Tenure
53yo
Average Age
Experienced Management: CERE's management team is considered experienced (3.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 5.3yrs | US$11.23m | 0.0086% $ 659.6k | |
President | less than a year | no data | 0.13% $ 10.3m | |
Independent Director | 4.8yrs | US$510.98k | 0.025% $ 1.9m | |
Independent Director | 5.5yrs | US$499.32k | 0.016% $ 1.2m | |
Independent Director | 3.2yrs | US$485.48k | 0% $ 0 | |
Lead Independent Director | 5.3yrs | US$562.57k | 0.024% $ 1.8m | |
Independent Director | 5.5yrs | US$497.15k | 0% $ 0 | |
Independent Director | 5.5yrs | US$492.98k | 0% $ 0 | |
Independent Director | 5.5yrs | US$497.15k | 0% $ 0 | |
Independent Director | 3.3yrs | US$485.48k | 0% $ 0 | |
Independent Director | 1.8yrs | no data | no data | |
Independent Director | 3.2yrs | no data | no data |
5.0yrs
Average Tenure
63yo
Average Age
Experienced Board: CERE's board of directors are considered experienced (5 years average tenure).